(a) Bioinformatics analysis of SNPH or Miro2 differential expression in cancer versus normal tissues in public databases (Oncomine, TCGA, Prognoscan). , upregulation; , downregulation; C/N, cancer/normal; HR, hazard ratio. (b) IHC analysis of SNPH expression in breast carcinoma versus normal breast epithelium. Bulk, main lesion; IF, invasive front. Scale bar, 100 μm. (c) SNPH-positive cells in normal breast, CIS, bulk breast carcinoma or invasive front (IF). Each point corresponds to individual patients. ***P<0.0001 by unpaired t test with Welch's correction. (d) SNPH-positive cells in molecular subtypes of breast cancer. Lum, luminal. HER2, HER2-enriched. Each point corresponds to individual patients. **P=0.006–0.007; *P=0.01 by unpaired t test with Welch's correction. (e) SNPH-positive cells in breast cancer with no lymph node metastasis, ⩽10% of metastatic lymph nodes (<10%) or >10% metastatic lymph nodes (>10%). Data are represented as mean±s.e.m. **P=0.007 by Mann Whitney test. (f) Histologic analysis of liver metastases after intrasplenic injection of PC3 cells stably expressing vector or SNPH cDNA. Scale bar, 500 μm. (g) Number of liver metastatic foci per field in animals from f. Data are represented as mean±s.e.m. (n=15). ***P<0.0001 by Student's t test.